• March 2023: NHS approved Wegovy, a weight loss injection known as semaglutide. Wegovy mimics the hormone glucagon-like peptide-1 (GLP-1) and suppresses appetite. The NHS is set to offer Wegovy, a weight loss injection known as semaglutide, to thousands of people living with obesity in England.

• May 2022: The US Food and Drug Administration (FDA approved Eli Lilly and Company's Mounjaro (tirzepatide) injection as an adjunct to diet and exercise. It is to enhance glycemic control in adult patients with type 2 diabetes. A single molecule, Mounjaro is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

In this report, the Global Glucagon-like Peptide-1 (GLP-1) Agonists Market has been segmented by Product, Route of Administration, Drugs, End Users, and Geography.

Global Glucagon-like Peptide-1 (GLP-1) Agonists Market, Segmentation by Product

The Global Glucagon-like Peptide-1 (GLP-1) Agonists Market has been segmented by Product into Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, and Trulicity.

Ozempic stands out in the global GLP-1 agonists market, commanding over 30% of market share. Its effectiveness in controlling blood sugar levels and reducing cardiovascular risks in type 2 diabetes patients contributes to its robust positioning and continued growth.

Rybelsus captures nearly 12% of the market, positioning itself as the only oral GLP-1 receptor agonist available. Its ease of use, combined with strong efficacy, makes it a compelling option for patients seeking an alternative to injectables.

Saxenda holds approximately 10% market share, primarily targeting weight management. Its proven results in supporting weight loss among patients with obesity have established it as a key player in this segment.

Wegovy claims about 15% of the global GLP-1 agonist market. Its higher-dose formulation of semaglutide delivers superior weight loss outcomes, making it a significant advancement in obesity treatment.

Mounjaro has swiftly captured around 8% of the market, setting itself apart with its dual GIP and GLP-1 receptor agonist action. Its combination of glucose control and weight reduction drives its rising popularity.

Zepbound is carving out roughly 5% market share with its innovative multi-receptor targeting approach. Its impressive clinical outcomes are propelling its rapid adoption and market expansion.

Victoza maintains a stable 7% share in the global GLP-1 agonist market. Known for its consistent glucose-lowering efficacy, it remains a trusted choice, though facing mounting competition from newer entrants.

Trulicity commands about 13% of the market, distinguished by its convenient once-weekly dosing and proven cardiovascular benefits. Its user-friendly approach continues to resonate with both patients and healthcare providers.

Global Glucagon-like Peptide-1 (GLP-1) Agonists Market, Segmentation by Route of Administration

The Global Glucagon-like Peptide-1 (GLP-1) Agonists Market has been segmented by Route of Administration into Oral, Parenteral, and Others.

The oral segment comprises about 15% of the global GLP-1 agonists market, driven by the popularity of convenient, non-injectable therapies like Rybelsus. This category is expanding, appealing to patients seeking easier, needle-free treatment options.

Parenteral administration dominates with approximately 80% of the market share, led by widely used injectable options such as Ozempic, Wegovy, and Trulicity. Its proven clinical efficacy and broad adoption have solidified its leading position.

The "Others" segment contributes roughly 5% of the market, encompassing alternative delivery routes and innovative formulations under development. Though relatively small, this segment presents opportunities for future growth and diversification in GLP-1 therapies.

Global Glucagon-like Peptide-1 (GLP-1) Agonists Market, Segmentation by Drugs

The Global Glucagon-like Peptide-1 (GLP-1) Agonists Market has been segmented by Drugs into Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide.

Dulaglutide, marketed under the brand name Trulicity, holds a robust 13% share of the global GLP-1 agonists market. Its once-weekly injection schedule and strong cardiovascular benefits make it a popular choice for managing type 2 diabetes.

Exenatide, available as Byetta and Bydureon, captures about 6% of the market. Its availability in both twice-daily and once-weekly formulations offers flexibility, though competition from newer agents is impacting its market hold.

Liraglutide, marketed as Victoza, maintains an estimated 7% market share globally. Known for its effectiveness in controlling blood sugar levels, it continues to be a reliable treatment despite increased competition from newer GLP-1 therapies.

Lixisenatide, branded as Lyxumia, accounts for roughly 3% of the market. Its solid glucose-lowering efficacy is recognized, but the rise of longer-acting alternatives has limited its market expansion.

Semaglutide, sold under the brand name Ozempic, leads the segment with over 30% market share. Its powerful glycemic control, significant cardiovascular protection, and convenient dosing have made it a frontrunner in the global GLP-1 market.

Global Glucagon-like Peptide-1 (GLP-1) Agonists Market, Segmentation by End Users

The Global Glucagon-like Peptide-1 (GLP-1) Agonists Market has been segmented by End Users into Hospitals, Specialty Clinics, and Others.

Hospitals command a strong 50% share of the global GLP-1 agonists market. Their comprehensive healthcare infrastructure and large patient volumes make them pivotal in delivering GLP-1 therapies to patients with diabetes and related conditions.

Specialty clinics contribute approximately 35% of the market, focusing on specialized care for diabetes and metabolic disorders. Their expertise and personalized treatment approaches drive the growing demand for GLP-1 agonists in this sector.

The "Others" segment, including pharmacies and outpatient care centers, holds roughly 15% of the market. These settings enhance patient access to GLP-1 agonists, supporting broader distribution beyond major healthcare facilities.

Global Glucagon-like Peptide-1 (GLP-1) Agonists Market, Segmentation by Geography

In this report, the Global Glucagon-like Peptide-1 (GLP-1) Agonists Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Share (%), by Geographical Region, 2024

North America dominates the global GLP-1 agonists market with an estimated 40% market share. Its high diabetes prevalence, advanced healthcare infrastructure, and strong uptake of innovative treatments position the region as a clear leader.

Europe accounts for roughly 30% of the global market, driven by increasing awareness of diabetes care, supportive healthcare policies, and growing adoption of GLP-1 therapies. These factors contribute to the region's steady growth.

Asia Pacific captures approximately 18% of the market, bolstered by rapid urbanization, rising diabetes incidence, and improved access to healthcare. The region is emerging as a key growth driver for the GLP-1 agonists market.

Middle East and Africa comprise about 7% of the market, with growth fueled by rising healthcare investments and enhanced diabetes awareness. Though currently smaller, the region shows promise for future expansion.

Latin America holds around 5% of the market, driven by gradual healthcare improvements and increasing diabetes prevalence. The region is witnessing a steady rise in the adoption of GLP-1 therapies.